Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Current Deferred Revenue: 2020-2023

Historic Current Deferred Revenue for Molecular Partners Ag (MOLN) over the last 4 years, with Dec 2023 value amounting to $4,825.

  • Molecular Partners Ag's Current Deferred Revenue rose 11.23% to -$5,001 in Q3 2024 from the same period last year, while for Sep 2024 it was -$5,001, marking a year-over-year increase of 11.23%. This contributed to the annual value of $4,825 for FY2023, which is 27.48% down from last year.
  • Per Molecular Partners Ag's latest filing, its Current Deferred Revenue stood at $4,825 for FY2023, which was down 27.48% from $6,653 recorded in FY2022.
  • Over the past 5 years, Molecular Partners Ag's Current Deferred Revenue peaked at $7.7 million during FY2020, and registered a low of $4,825 during FY2023.
  • For the 3-year period, Molecular Partners Ag's Current Deferred Revenue averaged around $14,061, with its median value being $6,653 (2022).
  • Data for Molecular Partners Ag's Current Deferred Revenue shows a maximum YoY crashed of 99.60% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Molecular Partners Ag's Current Deferred Revenue stood at $7.7 million in 2020, then slumped by 99.60% to $30,704 in 2021, then plummeted by 78.33% to $6,653 in 2022, then fell by 27.48% to $4,825 in 2023.